A 45-year-old, female middle school choral teacher presented with gradually worsening dysphonia. She described a decrease in her upper range, diffi culty with her passaggio, and a slight decrease in breath support. Although her complaints primarily involved singing, during the school year she also had experienced intermittent hoarseness, occasional "tight throat" when teaching, and vocal fatigue that increased in severity and duration toward the end of the school year. She denied voice breaks, weak voice, breathiness, decreased projection, and diffi culty producing loud or soft volume. Her dysphonia was exacerbated by both prolonged speaking and singing, and by lack of sleep. She had occasional throat clearing with phlegm, postnasal drip, and cough. She is a nonsmoker and denied any
history of laryngeal trauma or thyroid disease.
Videostroboscopic examination of the larynx revealed Reinke edema and changes associated with laryngopharyngeal refl ux (LPR), including interarytenoid erythema, posterior "cobblestoning, " and vocal fold edema (fi gure 1). Th e refl ux fi nding score was 7.
Common causes of Reinke edema include smoking, voice abuse, laryngopharyngeal refl ux, and hypothyroidism. Reinke edema is characterized by increased fi brin and vasculature, as well as accumulation of gelatinous fl uid in Reinke's space (fi gure 2). Th e vocal folds may appear swollen, fl oppy, or polypoid; hence, alternative names such as polypoid corditis, polypoid degeneration, and edematous hypertrophy have been used to describe this process. Th e condition tends to Continued on page 158 tinnitus in hypertensive and/or diabetic patients. 18 In contrast to the fi ndings of Bauer and Brozoski, 13 our study found that a positive history of acoustic trauma did not aff ect tinnitus response to gabapentin. According to our investigation, other factors-such as tinnitus sound type, accompanying symptoms, and duration-had no infl uence on the eff ect of gabapentin on tinnitus.
If gabapentin is found to be eff ective in relieving tinnitus in any particular case, it probably should be continued at the minimum eff ective dose for the long term or even for the patient's lifetime. Because tinnitus can be eliminated with doses of gabapentin as low as 600 mg/day, we recommend that this drug be started at a low dose and increased slowly to as high as 1,800 mg/day in order to achieve the required result. Further studies in larger groups are needed to confi rm reports that gabapentin is eff ective in diabetic patients.
In summary, we conclude that although there was no statistically signifi cant overall diff erence between gabapentin and placebo in treating tinnitus in our study, patients whose tinnitus is accompanied by hypertension, diabetes, and/or dyslipidemia may benefi t from gabapentin.
